Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation

Lung Cancer

Volumn 83, Issue 2, 2014, Pages 300-301

  Villaruz, Liza C ^a   Socinski, Mark A ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

FBXW7 mutation; Lung adenocarcinoma; MTOR inhibitor; Next generation sequencing; Temsirolimus

Indexed keywords

B RAF KINASE; CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; K RAS PROTEIN; PACLITAXEL; PEMETREXED; TEMSIROLIMUS;

ADRENALECTOMY; ADULT; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; FBXW7 GENE; FEMALE; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG RESECTION; MEDIASTINOSCOPY; MEDIASTINUM LYMPHADENOPATHY; MULTIPLE CYCLE TREATMENT; PALLIATIVE THERAPY; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; WEIGHT GAIN;

FBXW7 MUTATION; LUNG ADENOCARCINOMA; MTOR INHIBITOR; NEXT GENERATION SEQUENCING; TEMSIROLIMUS;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CELL CYCLE PROTEINS; DRUG RESISTANCE, NEOPLASM; F-BOX PROTEINS; FEMALE; GLUTAMATES; GUANINE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MOTOR ACTIVITY; MUTATION; NEOPLASM METASTASIS; RECURRENCE; REMISSION INDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; UBIQUITIN-PROTEIN LIGASES; WEIGHT GAIN;

EID: 84892836775     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.11.018     Document Type: Article

References (6)

1. Mok T.S. Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol 2011, 8:661-668.
2. Johnson B.E., Kris M.G., Berry L.D., Kwiatkowski D.J., Iafrate A.J., Varella-Garcia M., et al. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: the Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2013, 31. (suppl; abstr 8019).
3. Mao J.H., Perez-Losada J., Wu D., Delrosario R., Tsunematsu R., Nakayama K.I., et al. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 2004, 432:775-779.
4. Mao J.H., Kim I.J., Wu D., Climent J., Kang H.C., DelRosario R., et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008, 321:1499-1502.
5. Akhoondi S., Sun D., von der Lehr N., Apostolidou S., Klotz K., Maljukova A., et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 2007, 67:9006-9012.
6. Woo Lee J., Hwa Soung Y., Young Kim S., Woo Nam S., Sang Park W., Young Lee J., et al. Somatic mutation of hCDC4 gene is rare in lung adenocarcinomas. Acta Oncol 2006, 45:487-488.